In an effort to improve clinical trial design and data research management, Dutch blockchain company Triall announced that it had teamed up with Mayo Clinic, an American non-profit medical center.
A 2-year multi-center pulmonary arterial hypertension clinical trial involving 10 research facilities and over 500 patients across the US will be supported on Triall’s e-Clinical platform from September onwards.
The application will assist with tasks including data capture, study monitoring, document management, and consent.
According to Triall, the goal of the partnership is to use its blockchain technology to establish an immutable public ledger audit trail — improving the clinical trial integrity.
This ensures that no one can alter the records, which provides a sense of trust for investigators, regulators, and stakeholders when they review and assess said trial-related data.
It is estimated to cost $19 million on average when a clinical trial researching new drugs or therapies is being conducted in the US.
From the preclinical stage until the end, the approval rates for new chemical entities and biologics normally range between 10% to 20%, and can often take years of research.
Verial eTMF, which was introduced by Triall in 2018, is the company’s first blockchain product. It serves as a tool for researchers to produce verifiable proof of authenticity of clinical trial records, including patient diagnosis data.
With e-Clinical, the company is developing APIs that allow existing third-party clinical trial software providers to use Triall’s blockchain infrastructure. The native TRL token is intended to serve ecosystem-related needs, like compensating clinical trial participants. Triall hopes to continue working with Mayo Clinic on decentralized medical research if the token succeeds.
